Movement Alert｜Veradermics, Inc. Intraday Rise 5.01% in Regular Trading, Clinical Progress and Cash Position Remain Supportive

Market Focus10-21

On October 21, Veradermics, Inc. rose 5.01% in Regular Trading, trading at $133.47 per share, with turnover of $5.5873 million.

The move appears tied to continued market focus on the company’s lead candidate VDPHL01 and its relatively strong cash position. Recent publicly disclosed updates showed VDPHL01 met all primary and key secondary endpoints in a phase 2/3 trial for male pattern hair loss, while a phase 2 study in female pattern hair loss indicated improvement in most participants after six months, with no treatment-related serious adverse events or cardiac adverse events reported.

Financially, the company previously reported about $819.9 million in cash and marketable securities, and management said that level should support operations through 2030. Relative to large Pharmacy peers, recent sector moves were mixed, with Eli Lilly down 0.74%, Johnson & Johnson down 1.06%, Merck up 0.15%, Pfizer down 0.22%, and AstraZeneca PLC up 0.45%.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment